The role of aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?

被引：1
|
作者：
Donderski, Rafal [1 ]
Manitius, Jacek [1 ]
机构：
[1] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Nephrol Hypertens & Internal Med, Torun, Poland
来源：
ARTERIAL HYPERTENSION | 2019年 / 23卷 / 01期
关键词：
aldosterone; chronic kidney disease; hypertension; cardiovascular risk; aldosterone antagonists; STAGE RENAL-DISEASE; RESISTANT HYPERTENSION; ALDACTONE THERAPY; HEART-FAILURE; DOUBLE-BLIND; SPIRONOLACTONE; HEMODIALYSIS; FIBROSIS; PROGRESSION; STIFFNESS;
D O I：
10.5603/AH.a2018.0016
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
Aldosterone is a mineralocorticoid hormone which plays a pivotal role in water and electrolytes balance. Moreover, aldosterone exerts a deleterious influence on the cardiovascular system and kidneys. In this review, we wanted to show mechanisms of aldosterone related organ damage, the role of aldosterone in kidney diseases, hypertension and therapeutic benefits related with aldosterone receptors blockade.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 46 条
  • [1] Role of mineralocorticoid receptor antagonists in kidney diseases
    Patel, Vishal
    Joharapurkar, Amit
    Jain, Mukul
    DRUG DEVELOPMENT RESEARCH, 2021, 82 (03) : 341 - 363
  • [2] Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome: Role of the Mineralocorticoid Receptor Antagonists
    Ronconi, Vanessa
    Turchi, Federica
    Appolloni, Gloria
    di Tizio, Valentina
    Boscaro, Marco
    Giacchetti, Gilberta
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (02) : 238 - 246
  • [3] Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
    Barrera-Chimal, Jonatan
    Girerd, Sophie
    Jaisser, Frederic
    KIDNEY INTERNATIONAL, 2019, 96 (02) : 302 - 319
  • [4] Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016
    Epstein, Murray
    Duprez, Daniel A.
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (07): : 661 - 666
  • [5] Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Alexandrou, Maria-Eleni
    Theodorakopoulou, Marieta P.
    Sarafidis, Pantelis A.
    KIDNEY AND DIALYSIS, 2022, 2 (02): : 163 - 182
  • [6] Mineralocorticoid receptor antagonists as a treatment paradigm for cardiovascular and kidney diseases
    Nishiyama, Akira
    Nakano, Daisuke
    Hitomi, Hirofumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 18P - 18P
  • [7] Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review
    Omidkhoda, Navid
    Vakilian, Farveh
    Mohammadpour, Amir H.
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (31) : 3862 - 3870
  • [8] Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
    Gilyarevsky, S. R.
    Ladygina, D. O.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2023, 19 (04) : 403 - 412
  • [9] Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection
    Liu, Zige
    Xie, Boji
    Pang, Shuting
    Xie, Yuli
    Jili, Mujia
    Mo, Zengnan
    Li, Wei
    Yang, Rirong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (08):
  • [10] ROLE OF ANGIOTENSIN RECEPTOR BLOCKERS (ARB) IN THE TREATMENT OF HYPERTENSION. FROM EVIDENCE TO CLINICAL PRACTICE
    Barrios Alonso, V.
    Tomas Zarlenga, J. P.
    Calderon Montero, A.
    Escobar Cervantes, C.
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2005, 17 : 70 - 82
12345